Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 139

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 139
---
 Plan) Registration Statement on Form S-8, as Exhibit 99.2 February 28, 2024 10.10** Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award) Registration Statement on Form S-8, as Exhibit 99.3 December 22, 2021 10.11** Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan) Annual Report on Form 10-K, as Exhibit 10.11 November 29, 2023 10.12** Executive Incentive Plan, adopted December 12, 2006 Annual Report on Form 10-K, as Exhibit 10.11 December 14, 2006 10.13** Arrowhead Pharmaceuticals, Inc. Inducement Plan Quarterly Report on Form 10-Q, as Exhibit 10.1 May 9, 2024 10.14** Employment Agreement between Arrowhead and Dr. Christopher Anzalone, dated June 11, 2008 Current Report on Form 8- K, as Exhibit 10.1 June 13, 2008 10.15** Amendment to Employment Agreement between Arrowhead and Dr. Christopher Anzalone, effective May 12, 2009 Annual Report on Form 10-K, as Exhibit 10.8 December 22, 2009 10.16† Collaboration Agreement by and among Alnylam Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., dated October 29, 2009 † Annual Report on Form 10-K, as Exhibit 10.36 December 20, 2011 10.17† Non-Exclusive License Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011† Annual Report on Form 10-K, as Exhibit 10.33 December 20, 2011 10.18† License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.† Quarterly Report on Form 10-Q, as Exhibit 10.1 August 12, 2014 10.19† Second Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016† Annual Report on Form 10-K, as Exhibit 10.19 December 14, 2016 Incorporated by Reference